Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.

One popular health platforms is promoting GLP-1 microdosing for weight loss: But how safe and effective is this approach?

Doctors advise most patients on GLP-1 obesity drugs such as Wegovy and Zepbound to stay on them to keep the weight off, but ...

The weight loss conversation has been transformed in recent years by the rise of GLP-1 medications—drugs originally developed ...

The Hunting Wives' actress Chrissy Metz gets candid in a new cover story for PEOPLE on her thoughts about using weight loss ...

Next-generation weight-loss pills could hit the market in the coming months, with new data raising a key question: Will ...

In the first Phase 3 trial of its once-daily oral GLP-1 pill in people with obesity, drugmaker Eli Lilly said Thursday that ...

Eli Lilly's experimental oral pill, orforglipron, shows promise in obesity treatment, with participants experiencing an ...

Oikos Fusion offers a nutrient-dense dairy drink designed to support muscle mass and digestive health during weight loss ...

By Dennis Thompson HealthDay ReporterFRIDAY, Aug. 8, 2025 (HealthDay News) — More than 1 in 10 Americans have used a GLP-1 ...

In a clinical trial, the company's weight loss pill resulted in a nearly 12% weight loss at 72 weeks for participants who took the highest dose of the medication. On average, participants lost 7.8% to ...

New studies found that Americans with type 2 diabetes who are taking GLP-1 drugs like Ozempic and Mounjaro could face an ...